



3004 Rec'd PCT/PTO 29 JUL 2005

PET 45

506.44793X00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. SAKI, et al.
Application No.: 10/525,324
Filed: February 22, 2005
For: AGENT FOR PREVENTION AND/OR TREATMENT OF
ITCHING
Art Unit: TBD
Examiner: TBD

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97 AND 1.98

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

July 29, 2005

Sir:

Pursuant to applicants' duty of disclosure, enclosed please find documents to be considered during examination of the above-identified application. Also enclosed is a Form PTO/SB/08A&B, listing the enclosed documents.

Of the enclosed documents, No. WO 02/24222, No. EP 549352 and pages 786-793 of Merck Manuel of Diagnosis and Therapy (17th Ed., 1999) were cited in the International Search Report for International (PCT) Application No. PCT/IB2003/003475, filed August 22, 2003 of which the above-identified application is a national stage application filed under 35 U.S.C. 371. The remaining documents listed on the enclosed Form are cited in applicants' specification, for example, on pages 2-5 thereof.


To the extent that the enclosed documents are not in English, it is respectfully submitted that requirements of 37 C.F.R. 1.98(a)(3) are satisfied by discussion of the documents in the specification of the above-identified application; and, moreover, with the exception of the article Miocque, et al., in European Journal of Medicinal Chemistry, are further satisfied by English abstracts/summaries.

In view of the foregoing, it is respectfully submitted that all applicable requirements of 37 C.F.R. 1.97 & 1.98 have been satisfied, in connection with present submission of the enclosed documents. Accordingly, consideration of the enclosed documents, upon examination of the above-identified application, is respectfully requested.

Applicants request any shortage or excess in fees in connection with the filing of this paper, including extension of time fees, and for which no other form of payment is offered, be charged or credited to Deposit Account No. 01-2135 (Case: 506.44793X00).

Respectfully submitted,

ANTONELLI, TERRY, STOUT & KRAUS, LLP.


William I. Solomon
Registration No. 28,565

WIS/gjb
1300 N. Seventeenth Street
Suite 1800
Arlington, Virginia 22209
Tel: 703-312-6600
Fax: 703-312-6666

July 29, 2005

4 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,324
				Filing Date	February 22, 2005
				First Named Inventor	M. SAKI
				Art Unit	TBD
				Examiner Name	TBD
				Attorney Docket Number	506.44793X00
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		JP A 9-124500	5/13/97	Kuraishi, et al.		
		WO 02/24222 A2	3/28/ 02	The Cleveland Clinic Foundation		
		EP 0 549 352 A2	6/30/93	Kyowa Hakko Kogyo Co., Ltd.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/525,324
Filing Date	February 22, 2005
First Named Inventor	M. SAKI
Group Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	506.44793X00

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

JUL 29 2005

(Use as many sheets as necessary)

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Y. Murata, et al., Abnormal Expression of sphingomyelin Acylase in Atopic Dermatitis: An Etiologic Factor for Ceramide Deficiency?, Journal, June 1996, Pages 1242-1249, Vol. 106, No. 6, The Journal of Investigative Dermatology, United States	
		K. Zhu, et al., Sphingosylphosphorylcholine and Lysophosphatidylcholine are Ligands for the G Protein-Coupled Receptor GPR4, Journal, November 2001, Pages 41325-41335, Vol. 276, No. 44, The Journal of Biological Chemistry, United States	
		K. Higuchi, et al., Sphingosylphosphorylcholine is an Activator of Transglutaminase Activity in Human Keratinocytes, Journal, 2001, Pages 1562-1570, Vol. 42, Journal of Lipid Research, United States	
		A.K. Ryborg, et al., Intracutaneous Injection of Lysophosphatidylcholine Induces Skin Inflammation and Accumulation of Leukocytes, Report, 2000, Pages 242-246, Vol. 80, Acta Derm Venereol, Denmark	
		Bacterial Infections of the Skin, Book, Pages 787-793, Chap. 112, Sec. 10, National Library of Medicine, United States	
		J. Lehuède, et al., Aminomethylation de L'homoacridane, de L'iminodibenzyle et de L'iminostilbene, 1981, Pages 1851-191, No. 5-6, Bulletin de la Société Chimique de France, France	
		M. Miocque, et al., Derives de L'imipramine: Aminomethylation de la Diphenylamine et de L'iminodibenzyle, Journal, May-June 1977, Pages 219-225, Volume 12, No. 3, European Journal of Medicinal Chemistry, France	
		G. Imokawa, et al., Sphingosylphosphorylcholine is a Potent Inducer of Intercellular Adhesion Molecule-1 Expression in Human Keratinocytes, Journal, January 1999, Pages 91-96, Vol. 112, No. 1, The Journal of Investigative Dermatology, United States	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2